Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

Florou, Vaia; Rosenberg, Andrew E; Wieder, Eric; Komanduri, Krishna V; Kolonias, Despina; Uduman, Mohamed; Castle, John C; Buell, Jennifer S; Trent, Jonathan C; Wilky, Breelyn A

Florou, Vaia; Rosenberg, Andrew E; Wieder, Eric; Komanduri, Krishna V; Kolonias, Despina; Uduman, Mohamed; Castle, John C; Buell, Jennifer S; Trent, Jonathan C; Wilky, Breelyn A.

Afiliação

Florou V; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA. vaia.florou@hsc.utah.edu.
Rosenberg AE; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Wieder E; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Komanduri KV; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Kolonias D; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Uduman M; Agenus Inc., 3 Forbes Road, Lexington, MA, 02421, USA.
Castle JC; Agenus Inc., 3 Forbes Road, Lexington, MA, 02421, USA.
Buell JS; Agenus Inc., 3 Forbes Road, Lexington, MA, 02421, USA.
Trent JC; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Wilky BA; Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.

J Immunother Cancer ; 7(1): 285, 2019 Nov 06.

Article em En | MEDLINE | ID: mdl-31694703

RESUMO

Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells".

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Immunother Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google